- Raw materials
- Gastrointestinal Agents
- Oxabolone cipionate
Oxabolone 17-cyclopentanepropionate (Oxabolone cipionate) API Manufacturers & Suppliers
0 verified results
All Oxabolone cipionate data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Oxabolone cipionate | CAS No: 1254-35-9 | GMP-certified suppliers
A medication that serves as an anabolic steroid primarily used illicitly to enhance athletic performance by promoting androgenic and anabolic effects.
Therapeutic categories
Primary indications
- Used as a performance enhancing drug illicitly in athletes
Product Snapshot
- Oxabolone cipionate is an injectable anabolic steroid formulation
- It is primarily used illicitly as a performance-enhancing agent in sports
- The compound remains experimental and is not approved by major regulatory authorities such as the FDA or EMA
Clinical Overview
Clinically, oxabolone cipionate is not approved for therapeutic use and is primarily recognized as a performance-enhancing agent illicitly employed by athletes. It acts by exerting androgenic effects, including the promotion of secondary sexual characteristics, which align with the typical pharmacodynamic profile of anabolic steroids. Although the precise mechanism of action is not detailed, its biological activity is attributed to androgen receptor binding following ester hydrolysis to the active oxabolone.
Pharmacokinetically, the cypionate ester prolongs release and activity in vivo by enhancing lipophilicity and delaying metabolism. As with related anabolic steroids, metabolism is likely hepatic with subsequent renal excretion. Oxabolone cipionate is categorized among drugs that are mainly renally excreted, which is consistent with steroid clearance pathways. Specific absorption, distribution, metabolism, and excretion (ADME) parameters are not comprehensively described in literature.
Safety and toxicity considerations mirror those associated with anabolic steroid use, including risks of androgenic side effects and potential endocrine disruption. The compound’s use remains experimental without authorization for medical application, reflecting its regulatory status and associated safety profile concerns. Importantly, oxabolone cipionate is prohibited in competitive sports due to its potential for performance enhancement.
From an API sourcing perspective, stringent quality control is critical given the compound’s complex steroid structure and illicit usage context. Procurement should ensure compliance with applicable regulatory standards and verification of purity and identity to prevent contamination and assure batch-to-batch consistency. Reliable supply chains must be established to mitigate risks associated with unauthorized manufacture or distribution.
Identification & chemistry
| Generic name | Oxabolone cipionate |
|---|---|
| Molecule type | Small molecule |
| CAS | 1254-35-9 |
| UNII | 5RXY50Q01N |
| DrugBank ID | DB13185 |
Pharmacology
| Summary | The compound acts as an androgen receptor agonist, promoting the development of male secondary sexual characteristics. It exerts anabolic effects by enhancing protein synthesis and muscle growth. Its primary pharmacodynamic action involves modulation of androgenic pathways. |
|---|---|
| Pharmacodynamics | Androgenic effects include enhanced secondary sexual characteristics. |
ADME / PK
| Metabolism | The prodrug oxabolone cipionate is converted to oxabolone. Oxabolone is then metabolized into 4-Hydroxyestr-4-en-3,17-dione (M2) which is the most abundant metabolite via oxidation of the 17-hydroxyl group. 4-Hydroxyestran-3,17-dione (M1) is formed by reduction of the A ring double bond along with the oxidation of the 17-hydroxyl group. Three isomeric compounds exist as another metabolite, as the 3α,4-dihydroxy-5α-estran-17-one, 3α,4-dihydroxy-5β-estran-17-one, and 3β,4-dihydroxy-5α-estran-17-one . |
|---|---|
| Route of elimination | The metabolites and unchanged form of oxabolone can be detected in the urine . |
| Clearance | The elimination on the first day following intravenous injection of oxabolone cipionate is slow and reaches a rapid excretion phase with the maximum urinary level in the fifth day of administration . |
Formulation & handling
- Oxabolone cipionate is a small molecule steroid ester with low water solubility, indicating formulation challenges for aqueous solutions.
- Primarily suited for injectable formulations due to its chemical nature and lipophilicity.
- Requires protection from hydrolysis and storage under controlled conditions to maintain stability.
Regulatory status
Oxabolone cipionate is a type of Gastrointestinal Agents
Gastrointestinal Agents belong to the pharmaceutical API category that focuses on treating disorders and ailments related to the digestive system. These agents play a crucial role in addressing various gastrointestinal conditions, such as acid reflux, ulcers, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD).
One of the key types of gastrointestinal agents is proton pump inhibitors (PPIs), which work by reducing the production of stomach acid. PPIs help in treating conditions like gastroesophageal reflux disease (GERD) and peptic ulcers. Another essential class of agents is antacids, which neutralize excessive stomach acid, providing relief from heartburn and indigestion.
Gastrointestinal agents also include antispasmodics that alleviate abdominal cramps and spasms associated with conditions like IBS. These drugs work by relaxing the smooth muscles of the digestive tract. Additionally, there are drugs categorized as laxatives that aid in relieving constipation by promoting bowel movements.
Moreover, certain gastrointestinal agents act as antiemetics, effectively reducing nausea and vomiting. These drugs are particularly useful for patients undergoing chemotherapy or experiencing motion sickness.
Pharmaceutical companies develop and manufacture a wide range of gastrointestinal agents in various forms, including tablets, capsules, suspensions, and injections. These agents are typically formulated using active pharmaceutical ingredients (APIs) and other excipients to ensure their efficacy and safety.
In conclusion, gastrointestinal agents form a vital category of pharmaceutical APIs, providing relief from digestive disorders and improving overall gastrointestinal health. The availability of diverse agents catering to different conditions ensures that patients can receive targeted treatment for their specific gastrointestinal needs.
